Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
November 7, 2018 8:57 AM ESTCowen analyst Ken Cacciatore lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $200.00 (from $220.00) while maintaining a Outperform rating.
... MoreJazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital
November 7, 2018 8:56 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $203.00 (from $206.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ reported mixed 3Q results with revenue of $469mm below BMO/consensus $478mm/$483mm, and adj. EPS of $3.58 ahead of... More
Jazz Pharmaceuticals (JAZZ) PT Lowered to $184 at RBC Capital
November 7, 2018 7:22 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $184.00 (from $194.00) while maintaining a Outperform rating.
... More